CoChat

State-of-the-art strategies for targeting the DNA damage response in cancer

Open access
Pilié, Patrick G., Tang, Chad, Mills, Gordon B., Yap, Timothy A. · 2019 · Nature Reviews Clinical Oncology

The DOI matches its Crossref record; 244 of the 245 references it cites were found in a registry or an index.

Abstract

Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA damage response (DDR) and/or increased replication stress. These alterations promote the clonal evolution of cancer cells via the accumulation of driver aberrations, including gene copy-number changes, rearrangements and mutations; however, these same defects also create vulnerabilities that are relatively specific to cancer cells, which could potentially be exploited to increase the therapeutic index of anticancer treatments and thereby improve patient outcomes. The discovery that BRCA-mutant cancer cells are exquisitely sensitive to inhibition of poly(ADP-ribose) polymerase has ushered in a new era of research on biomarker-driven synthetic lethal treatment strategies for different cancers. The therapeutic landscape of antitumour agents targeting the DDR has rapidly expanded to include inhibitors of other key mediators of DNA repair and replication, such as ATM, ATR, CHK1 and CHK2, DNA-PK and WEE1. Efforts to optimize these therapies are ongoing across a range of cancers, involving the development of predictive biomarker assays of responsiveness (beyond BRCA mutations), assessment of the mechanisms underlying intrinsic and acquired resistance, and evaluation of rational, tolerable combinations with standard-of-care treatments (such as chemotherapeutics and radiation), novel molecularly targeted agents and immune-checkpoint inhibitors. In this Review, we discuss the current status of anticancer therapies targeting the DDR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41571-018-0114-z

Cites

244 of 244 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 244 references

Cited by

See all 1,189

Metadata

Authors
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Yap, Timothy A.
Venue
Nature Reviews Clinical Oncology
Published
2018-10-24
Volume
16
Issue
2
Pages
81-104
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
OpenAlex
W2898088739
Cited by
1,189
References
245
Citations by year
2026: 90 · 2025: 144 · 2024: 155 · 2023: 170 · 2022: 239 · 2021: 193 · 2020: 130 · 2019: 67 · 2018: 1
FWCI
10.47
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature Reviews Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (P50CA098258, U01CA217842, P30CA016672)
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
DNA damage response, cancer therapy, PARP inhibitors, synthetic lethality, BRCA mutations, ATM inhibitors, ATR inhibitors, CHK1 inhibitor, CHK2 inhibitors, DNA-PK inhibitor, WEE1 inhibitor, genomic instability, predictive biomarkers, drug resistance, combination therapy, DNA repair deficiency, clonal evolution
MeSH terms
Antineoplastic Agents, DNA Damage, DNA Repair, Humans, Mutation, Neoplasms, Treatment Outcome, Drug Resistance, Neoplasm, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: State-of-the-art strategies for targeting the DNA damage response in cancer. https://app.cochat.ai/papers/10.1038/s41571-018-0114-z
The paper
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019). State-of-the-art strategies for targeting the DNA damage response in cancer. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-018-0114-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.